Treating difficult crystal pyrophosphate dihydrate deposition disease

被引：13

作者：

Announ N. ^{[1
]}

Guerne P.-A. ^{[1
]}

机构：

[1] Hôpital Universitaire de Genève, Division de Rhumatologie, 1211 Genève 14

来源：

Current Rheumatology Reports | 2008年 / 10卷 / 3期

关键词：

Gout; Hemochromatosis; Anakinra; Tumor Necrosis Factor Inhibitor; Short Bowel Syndrome;

D O I：

10.1007/s11926-008-0037-2

中图分类号：

学科分类号：

摘要：

Calcium pyrophosphate dihydrate deposition disease is a common and potentially severe metabolic arthropathy. Early disease (in patients ≤ 60 years old) requires a search for one of the associated metabolic conditions, particularly hemochromatosis. Treatment is primarily symptomatic (no drug is known to prevent the progression of articular destruction). Nonsteroidal anti-inflammatory drugs and intra-articular or systemic glucocorticoids (in small amounts if use is prolonged) are the most useful treatments. Colchicine can be effective to treat recurring pseudogout, and magnesium can be effective on a preventive basis. Methotrexate showed interesting effectiveness in a small, uncontrolled series, and it can be used in the event of failure of the other treatments. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：228 / 234

页数：6

共 32 条

[1]

Doherty M., Dieppe P.A., Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy, Ann Rheum Dis, 42, SUPPL. 1, (1983)

[2]

Rosenthal A.K., Ryan L.M., Probenecid inhibits transforming growth factor-beta 1 induced pyrophosphate elaboration by chondrocytes, J Rheumatol, 21, pp. 896-900, (1994)

[3]

Sun Y., Reuben P., Wenger L., Et al., Inhibition of calcium phosphate-DNA coprecipitates induced cell death by phosphocitrates, Front Biosci, 10, pp. 803-808, (2005)

[4]

Bennett R.M., Lehr J.R., McCarty D.J., Crystal shedding and acute pseudogout. An hypothesis based on a therapeutic failure, Arthritis Rheum, 19, pp. 93-97, (1976)

[5]

Shinozaki T., Xu Y., Cruz T.F., Pritzker K.P., Calcium pyrophosphate dihydrate (CPPD) crystal dissolution by alkaline phosphatase: Interaction of alkaline phosphatase on CPPD crystals, J Rheumatol, 22, pp. 117-123, (1995)

[6]

Nuki G., Treatment of crystal arthropathy - history and advances, Rheum Dis Clin North Am, 32, (2006)

[7]

Pascual E., Management of crystal arthritis, Rheumatology (Oxford), 38, pp. 912-916, (1999)

[8]

Abramson S.B., Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs, Curr Opin Rheumatol, 4, pp. 295-300, (1992)

[9]

Rosenthal A.K., Ryan L.M., Treatment of refractory crystal-associated arthritis, Rheum Dis Clin North Am, 21, pp. 151-161, (1995)

[10]

Choy G., An update on the treatment options for gout and calcium pyrophosphate deposition, Expert Opin Pharmacother, 6, pp. 2443-2453, (2005)

← 1 2 3 4 →